Medgenics Inc (GNMX) Forecasted to Earn Q1 2017 Earnings of ($0.28) Per Share

Medgenics Inc (NASDAQ:GNMX) – Zacks Investment Research issued their Q1 2017 EPS estimates for shares of Medgenics in a report released on Monday. Zacks Investment Research analyst B. Marckx expects that the firm will post earnings of ($0.28) per share for the quarter. Zacks Investment Research also issued estimates for Medgenics’ Q2 2017 earnings at ($0.30) EPS and Q3 2017 earnings at ($0.29) EPS.

Other equities analysts also recently issued reports about the company. Jefferies Group LLC downgraded Medgenics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $10.00 to $2.50 in a research note on Tuesday, March 21st. Needham & Company LLC reiterated a “buy” rating and issued a $9.00 price target (down from $12.00) on shares of Medgenics in a research note on Tuesday, March 21st.

COPYRIGHT VIOLATION WARNING: “Medgenics Inc (GNMX) Forecasted to Earn Q1 2017 Earnings of ($0.28) Per Share” was first published by Mideast Time and is the sole property of of Mideast Time. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.mideasttime.com/medgenics-inc-gnmx-forecasted-to-earn-q1-2017-earnings-of-0-28-per-share/1590077.html.

Medgenics (NASDAQ:GNMX) opened at 1.85 on Tuesday. The stock’s market capitalization is $68.65 million. The stock’s 50 day moving average price is $4.50 and its 200-day moving average price is $5.03. Medgenics has a 52 week low of $1.50 and a 52 week high of $6.89.

A number of institutional investors have recently bought and sold shares of the company. Massey Quick & Co. LLC bought a new position in Medgenics during the fourth quarter worth about $126,000. State Street Corp increased its position in Medgenics by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the company’s stock worth $1,789,000 after buying an additional 46,149 shares during the last quarter. Oxford Asset Management bought a new position in Medgenics during the fourth quarter worth about $249,000. Birchview Capital LP bought a new position in Medgenics during the fourth quarter worth about $249,000. Finally, Opaleye Management Inc. bought a new position in Medgenics during the fourth quarter worth about $7,770,000. Institutional investors and hedge funds own 44.69% of the company’s stock.

In other news, major shareholder Philip R. Harper purchased 1,058,531 shares of the firm’s stock in a transaction that occurred on Friday, March 24th. The stock was acquired at an average cost of $1.78 per share, for a total transaction of $1,884,185.18. Following the completion of the purchase, the insider now owns 4,786,682 shares of the company’s stock, valued at $8,520,293.96. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 23.40% of the stock is currently owned by company insiders.

5 Day Chart for NASDAQ:GNMX

Receive News & Ratings for Medgenics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.